Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.065 USD | +0.75% | -4.77% | -34.29% |
May. 21 | The latest transactions by star managers | |
May. 20 | Sector Update: Health Care Stocks Mixed Pre-Bell Monday | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 3.39 times the sales for the current fiscal year, the company turns out to be overvalued.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Professional Information Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-34.99% | 4.02B | B | ||
-0.15% | 138B | A- | ||
+21.93% | 77.99B | B- | ||
-10.63% | 40.05B | B+ | ||
+14.69% | 38.07B | B+ | ||
-5.68% | 17.15B | B+ | ||
+11.51% | 14.88B | C+ | ||
+10.58% | 10.57B | B | ||
-10.60% | 4.63B | B | ||
+15.31% | 2.32B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CLVT Stock
- Ratings Clarivate Plc